Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics Licenses Cell Engineering Platform From MaxCyte

NEW YORK (GenomeWeb) – CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing deal for a cell transfection platform from MaxCyte.

Under the terms of the agreement, CRISPR Therapeutics and Casebia will obtain non-exclusive rights to commercial use of MaxCyte's Flow Electroporation technology for use in developing CRISPR/Cas9-based therapies for hemoglobin deficiencies and severe combined immunodeficiency.

The firm will make undisclosed upfront, milestone, and sales-based payments.

"It is important we prepare for the future by securing our access to the leading ex vivo delivery solution for both clinical and commercial use," CRISPR Therapeutics Chief Business Officer Samarth Kulkarni said in a statement.

MaxCyte's technology enables transfection of a variety of cell types at high efficiency, the company said. CRISPR Therapeutics and Casebia said they will use the technology to transfect hematopoietic stem cells.